Fibrinogen gamma-A chain precursor as a biomarker for Alzheimer's disease
Author Information
Author(s): Lee Joung Wook, Namkoong Hong, Kim Hyun Kee, Kim Sanghee, Hwang Dong Whi, Na Hae Ri, Ha Seon-Ah, Kim Jae-Ryong, Kim Jin Woo
Primary Institution: Bobath Memorial Hospital, The Catholic University of Korea, Yeungnam University
Hypothesis
The study aims to investigate candidate CSF biological markers in patients with mild cognitive impairment and Alzheimer's disease.
Conclusion
The CSF level of fibrinogen gamma-A chain precursor may be a candidate biomarker for Alzheimer's disease.
Supporting Evidence
- The study demonstrated elevated levels of fibrinogen gamma-A chain precursor protein in CSF from patients with mild cognitive impairment and Alzheimer's disease.
- Its expression was more prominent in the Alzheimer's disease group than in the mild cognitive impairment group.
- The findings suggest a correlation between the protein levels and disease severity.
Takeaway
Researchers found a protein in the fluid around the brain that could help detect Alzheimer's disease earlier.
Methodology
Proteomics approaches were applied to analyze CSF samples from patients with Alzheimer's disease, mild cognitive impairment, and normal controls.
Limitations
The study does not exclude the possibility that increased levels of fibrinogen gamma-A chain precursor may be due to increased blood levels or increased permeability across the blood-CSF barrier.
Participant Demographics
The study included 27 patients with Alzheimer's disease, 3 subjects with mild cognitive impairment, and 30 age-matched normal control subjects.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website